This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Cassava Sciences’s 8K filing here.
Cassava Sciences Company Profile
Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
Recommended Stories
- Five stocks we like better than Cassava Sciences
- Pros And Cons Of Monthly Dividend Stocks
- Disney: Forging a 3-Headed Sports Streaming Giant With Fubo Deal
- Best Stocks Under $10.00
- How Buffett’s Best and Worst Stock Bets Have Fared 5 Years Later
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Bill Ackman’s Bold Case for Fannie Mae and Freddie Mac
